Question 1

What is combined oxidative phosphorylation deficiency 19?

Accepted Answer

Combined oxidative phosphorylation deficiency 19 is a severe metabolic condition resulting from pathogenic variants in the LYRM4 gene and affects mitochondrial energy production. It primarily presents in early infancy with critical symptoms involving the respiratory and metabolic systems. Affected infants often show signs of metabolic acidosis, lactic acid buildup, and respiratory distress, among other features, with the condition being inherited in an autosomal recessive manner. Prevalence data are not well established, and there is considerable variability in symptom severity among affected individuals.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 19?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation deficiency 19 is marked by a constellation of findings. Nearly all affected individuals exhibit stridor, metabolic acidosis, lactic acid buildup in blood and urine, respiratory distress, and failure to thrive, which are considered characteristic and consistently observed features. In addition, a significant proportion of patients (approximately 30-79%) may experience feeding difficulties, gastroesophageal reflux, hepatic steatosis (both macrovesicular and microvesicular), elevated liver enzymes, and neuromuscular signs such as hypotonia and poor head control. That not all individuals experience all of these features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation deficiency 19?

Accepted Answer

The condition is caused by mutations in the LYRM4 gene, which plays a critical role in the proper functioning of the mitochondrial oxidative phosphorylation system. It is inherited in an autosomal recessive pattern, meaning that an affected individual has received a pathogenic variant from both parents, who are typically asymptomatic carriers. This inheritance pattern implies that there is a 25% chance in each pregnancy for carrier parents to have an affected child. Genetic counseling is recommended to help families understand the implications and recurrence risks. Associated genes include LYRM4.

Question 4

How is combined oxidative phosphorylation deficiency 19 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 19 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is combined oxidative phosphorylation deficiency 19 diagnosed?

Accepted Answer

Diagnosis of combined oxidative phosphorylation deficiency 19 is confirmed through molecular genetic testing that identifies pathogenic variants in the LYRM4 gene. In addition to genetic testing, clinicians evaluate the clinical presentation, including the characteristic findings of metabolic acidosis, lactic acidemia, respiratory distress, and failure to thrive. Laboratory investigations noting elevated lactate levels in blood, urine, or by MRS further support the diagnosis. Because many of these symptoms can overlap with other metabolic conditions, definitive diagnosis relies on genetic confirmation.

Question 6

Are there treatments for combined oxidative phosphorylation deficiency 19?

Accepted Answer

Currently, management of combined oxidative phosphorylation deficiency 19 focuses on supportive care and symptom management, with treatment tailored to the individual’s needs. A multidisciplinary approach is essential, involving metabolic specialists, respiratory therapists, and nutrition experts who can provide regular surveillance to monitor potential complications. Although there are no specific foundational therapies or FDA-approved treatments for this condition, ongoing management includes addressing metabolic acidosis, ensuring adequate nutrition, and supporting respiratory function. Patients should discuss treatment options with their healthcare team to determine which supportive measures may be most appropriate for their situation, and genetic counseling is recommended for families.

Question 7

What complications can arise from combined oxidative phosphorylation deficiency 19?

Accepted Answer

Complications from combined oxidative phosphorylation deficiency 19 can include severe metabolic acidosis and respiratory distress, which can be life-threatening, especially in infants. Additionally, affected individuals may experience feeding difficulties and poor growth, leading to failure to thrive. Regular monitoring by a healthcare team is important to manage these complications effectively.

Question 8

How does combined oxidative phosphorylation deficiency 19 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation deficiency 19 can be challenging for both patients and their families. Daily life may involve managing feeding difficulties, ensuring proper nutrition, and addressing respiratory issues. Families often need to work closely with a team of specialists to provide the best care and support for their loved ones.

Question 9

What is the prognosis for children with combined oxidative phosphorylation deficiency 19?

Accepted Answer

The prognosis for children with combined oxidative phosphorylation deficiency 19 varies widely. Factors such as the severity of symptoms, age at diagnosis, and access to specialized care can influence outcomes. While some infants may benefit from intensive supportive management, the condition remains serious and can be life-threatening in early stages.

Question 10

What specialists should families consult for combined oxidative phosphorylation deficiency 19?

Accepted Answer

Families dealing with combined oxidative phosphorylation deficiency 19 should consult a team of specialists, including metabolic specialists, respiratory therapists, and nutrition experts. This multidisciplinary approach is essential for effective management and monitoring of the condition. Genetic counseling is also recommended to help families understand the implications of the disease and plan for the future.

Kisho

combined oxidative phosphorylation deficiency 19

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

combined oxidative phosphorylation deficiency 19

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 19?

What are the symptoms of combined oxidative phosphorylation deficiency 19?

What causes combined oxidative phosphorylation deficiency 19?

How is combined oxidative phosphorylation deficiency 19 inherited?

How is combined oxidative phosphorylation deficiency 19 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 19?

What complications can arise from combined oxidative phosphorylation deficiency 19?

How does combined oxidative phosphorylation deficiency 19 affect daily life for patients and families?

What is the prognosis for children with combined oxidative phosphorylation deficiency 19?

What specialists should families consult for combined oxidative phosphorylation deficiency 19?

Explore clinical features